LY2928057

LY2928057 is a humanized IgG4 monoclonal antibody developed by Eli Lilly and Company that targets ferroportin, a key protein in iron metabolism. This antibody works by binding to ferroportin and blocking its interaction with hepcidin, which allows for continued iron efflux from cells even in the presence of hepcidin. This mechanism helps address iron-restricted anemia, particularly in chronic kidney disease (CKD) patients. By binding to ferroportin, LY2928057 prevents hepcidin from interacting with it, thereby: - Maintaining iron efflux from cells - Increasing serum iron levels - Elevating transferrin saturation - Reducing ferritin levels (indicating mobilization of iron stores)